HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
CD33 CART AML
This study is now recruiting.
This phase 1/2 study will determine the safety, feasibility, and efficacy of CD33 CART cells following lymphodepleting chemotherapy in patients with acute myeloid leukemia (AML). Patients who are between ages 1 to 30 years with relapsed or refractory AML will be eligible for this study.
